10-K: SBC Medical Group Reports Mixed 2025 Results Amid Strategic Shifts

SBC Medical Group Holdings Incorporated reported a 9.33% increase in net income for 2025, alongside strategic acquisitions and ongoing international expansion, despite a 15.48% decrease in total revenues.

Summary

• Net income increased by 9.33% to $51,045,023 in 2025 from $46,689,892 in 2024.
• Total revenues decreased by 15.48% to $173,607,489 in 2025 from $205,415,542 in 2024.
• Cash and cash equivalents significantly increased by 30.97% to $163,773,838 in 2025 from $125,044,092 in 2024.
• Strategic acquisitions in 2024-2025 include Aesthetic Healthcare Holdings (Singapore), MB career lounge (Japan), and a controlling interest in Waqoo, Inc. (Japan), plus a minority investment in OT Midco Holdings, LLC (US).
• A revised fee structure for franchisee clinics, effective April 1, 2025, contributed to a decrease in franchising and management services revenue.
• Identified continuing material weaknesses in internal control over financial reporting related to oversight of related party transactions and executive compensation.
• An additional share repurchase program of up to $20.0 million was authorized, effective December 31, 2025, through December 31, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a mixed report. While net income and cash position improved, the significant decline in total revenues and gross profit, coupled with ongoing material weaknesses in internal controls, presents concerns. Strategic acquisitions and technological investments are positive long-term moves, but their immediate impact on core revenue streams needs careful monitoring.

Positives

• Net income increased by 9.33% year-over-year to $51,045,023.
• Cash and cash equivalents significantly increased by 30.97% to $163,773,838.
• Cash flow from operating activities rose by 19.85% to $24,668,496.
• Successful international expansion through acquisitions in Singapore (Aesthetic Healthcare Holdings) and strategic investment in the U.S. (OrangeTwist).
• Acquired a controlling interest in Waqoo, Inc., a medical research and development company specializing in regenerative medicine, diversifying the business.
• Implemented a multi-brand strategy in Japan with the launch of SBC NEO Skin Clinic and Hada no Aozora Clinic to capture broader customer segments.
• Maintained a high average repeat customer rate of over 72% at franchisee clinics.
• Significant investment in and licensing of AI-powered simulation technology for medical training and procedural accuracy.
• Authorized a new $20.0 million share repurchase program, signaling confidence in future cash flow and commitment to shareholder value.
• Recognized a substantial gain on redemption of life insurance policies of $8,746,138 in 2025.
• Procurement revenue increased by 2.26% and rental services revenue increased by 42.69%.

Negatives

• Total revenues decreased by 15.48% from $205,415,542 in 2024 to $173,607,489 in 2025.
• Franchising revenue decreased by 24.72% due to a revised fee structure for medical corporations (MCs).
• Management services revenue decreased by 44.22% due to the discontinuation of clinic operation staff supporting services and the revised fee structure.
• Gross profit decreased by 18.43% from $156,050,507 in 2024 to $127,283,722 in 2025.
• Continuing material weaknesses in internal control over financial reporting were identified regarding oversight of related party transactions and executive compensation.
• The SBC brand clinic in Irvine, California, was permanently closed at the end of May 2025, and management services to U.S. clinics were discontinued.
• The company does not maintain product liability insurance for medical devices, products, and equipment sold as a purchasing agent.
• No business interruption insurance or key employee insurance is maintained for executive officers.
• As a holding company, cash flows depend on operating subsidiaries, which can be restricted by debt terms and legal limitations.
• No current plans to pay cash dividends on common stock in the foreseeable future.

Risks

• Dependence on operating subsidiaries for cash flows, which can be restricted by debt terms and legal restrictions.
• Potential need for additional capital, which may lead to dilution of existing stockholders or additional restrictions through debt financings.
• Inability to grow the franchise system, compete effectively, manage growth, or maintain the strength and reputation of the brand.
• Adverse publicity, misconduct, safety concerns, product recalls, product liability claims, or unethical/non-compliant conduct by the company or its partners could harm reputation and operating results.
• Significant cybersecurity incidents, disruptions to operating systems, or failure to safeguard personal information could lead to reputational, financial, legal, and operational consequences.
• Uncertainties with respect to the development and use of artificial intelligence in business may adversely affect business and reputation.
• Failure by Medical Corporations (MCs) and other independently operated clinics to comply with applicable laws and regulations, including the Medical Care Act in Japan and privacy laws, could result in penalties and reputational damage.
• International operations and expansion outside Japan subject the company to additional operational, regulatory, compliance, and market risks.
• Risks associated with strategic alliances, acquisitions, and minority investments, including integration challenges and the possibility that transactions do not achieve intended benefits.
• Involvement in litigation from time to time, potentially incurring substantial judgments, fines, legal fees, or other costs.
• Limited insurance coverage, which could subject the company to significant costs and business disruption if liabilities exceed coverage.
• Operations may be interrupted by utility shortages or stoppages, fire, natural disasters, or other calamities at or near facilities.
• Challenging macroeconomic conditions, financial or economic crises, and trade tariffs or other trade barriers may adversely affect franchisees, business partners, and customers.
• Disclosure controls and procedures were not effective as of December 31, 2025, due to material weaknesses in internal control over financial reporting, which could impair timely and accurate financial reporting or prevent fraud.
• Nasdaq may delist securities, limiting investor transactions, reducing liquidity, and affecting ability to obtain additional financing.
• Competition from senior management who cease working for the company, as non-competition agreements expire two years following the Business Combination.
• Any significant change in the customer reward program at franchisee and other alliance clinics could negatively impact the business.
• Limited experience in providing management services to franchisee clinics located outside of Japan.
• Business and prospects depend significantly on the ability to build the Shonan Beauty Clinic brand.
• Employees, agents, business partners, or subcontractors may engage in misconduct or other improper activities.
• Decline in the business of business partners or deterioration of relationships with them.
• Safety issues or public perceptions of safety issues concerning cosmetic services.
• Failure to comply with environmental and work safety laws and regulations.
• Exposure to fluctuations in currency exchange rates (primarily JPY/USD).
• Actual operating results may differ significantly from guidance and projections.
• An active market for securities may not develop, adversely affecting liquidity and price.
• The market price of common stock may decline due to various factors.
• Stockholders may experience dilution from future equity issuances.
• Securities or industry analysts may not publish research or reports, or their recommendations may change.
• Future sales by the company or its stockholders could cause the market price of common stock to decline.
• Reliance on emerging growth company exemptions could make securities less attractive to investors.
• The company may redeem unexpired public warrants prior to their exercise at a time disadvantageous for warrant holders.
• Securities holders may face limitations in connection with the issuance of shares upon the exercise of warrants, and additional state securities law requirements could apply if securities are delisted.
• Common stock and warrants may be subject to penny stock rules in the future, making resale more difficult.
• Significant costs are incurred as a public company, and management must devote substantial time to compliance initiatives.
• Delaware law and the company's certificate of incorporation and bylaws contain anti-takeover provisions.
• Exclusive forum provisions may limit stockholders' ability to choose the judicial forum for disputes.
• As a controlled company, the company qualifies for exemptions from certain corporate governance requirements.
• Highly concentrated voting power (CEO owns 85.2%) may prevent minority stockholders from influencing significant corporate decisions and result in conflicts of interest.
• Private Placement Warrants may have no value if the common stock price does not exceed their exercise price.
• A current registration statement is required for the exercise of Private Placement Warrants.
• Holders of Private Placement Warrants have no rights as common stockholders until they acquire common stock.

Future Outlook

The company plans to achieve its mission by maintaining and strengthening its market position and brand in the cosmetic medical treatment management market in Japan, Vietnam, and Singapore, while pursuing growth opportunities in the United States through strategic investments and alliances, and continuing to grow its global presence. It anticipates expanding its workforce and expects to drive higher corporate-level profitability by leveraging its existing support infrastructure, with general and administrative costs increasing at a slower rate than revenues as franchisee clinics grow. The company intends to continue targeted local and global marketing efforts to heighten brand awareness and will continue to collect and analyze medical data, develop innovative procedures and products, and obtain intellectual property rights. It is committed to making an additional $5.0 million cash contribution to OT Midco in December 2026 and will continue to evaluate and finalize additional enhancements to internal control systems, governance procedures, and approval processes to remediate identified material weaknesses.

Management Comments

• Our management team plans to conduct additional procedures and actions to mitigate risks of the short seller allegations that the Company may be subject to.
• Our management has concluded that the consolidated financial statements included in this Annual Report present fairly, in all material respects, the financial position, results of our operations and cash flows in accordance with U.S. generally accepted accounting principles (GAAP).
• Our management is committed to remediating these material weaknesses as promptly as practicable.

Industry Context

StockSavvy.ai notes that the cosmetic medical service and product industry is highly sensitive to customer preferences, economic conditions, and demographic trends, with a growing demand for non-invasive services. The company's multi-brand strategy and focus on technology, particularly AI-powered simulation, align with industry trends towards diversification and advanced solutions. Intense competition from both local and international players, coupled with rising operational costs due to inflation, presents ongoing challenges. The company's international expansion efforts are consistent with a globalizing industry, but also expose it to diverse regulatory and market risks. The strategic investments in regenerative medicine (Waqoo) and U.S. medical aesthetics (OrangeTwist) indicate a proactive approach to capturing emerging market segments and geographical diversification.

Comparison to Industry Standards

• The company's average repeat customer rate of over 72% is a strong indicator of customer loyalty, potentially outperforming general industry benchmarks, though specific comparative figures are not provided in the filing.
• The launch of SBC NEO Skin Clinic, specializing in non-invasive aesthetic dermatology leveraging advanced laser devices and treatments widely adopted in South Korea and Western markets, demonstrates an effort to match or exceed international standards in specific treatment areas.
• The utilization of AI models like GAN for a 'double AI simulation service,' trained on 600,000 double layer cases, positions the company at the forefront of technological adoption in cosmetic surgery, potentially offering a more advanced and standardized approach compared to traditional manual simulation methods used by competitors such as Aesthetic Medispa or Cynosure Lutronic.
• The company faces significant competition from major global players like Alma Lasers, Evolus, Inc., Galderma S.A., and Inmode Ltd., which possess substantially greater financial, technical, and marketing resources, indicating a challenging competitive landscape.

Management Changes

Corporate Governance

Legal Proceedings

• On February 11, 2026, a purported stockholder class action complaint was filed against the Company and its directors in the Court of Chancery of the State of Delaware, alleging violations under Delaware General Corporation Law Section 141(k) and Delaware common law, due to the company's charter wrongly restricting the removal of directors to only for cause. The complaint seeks unspecified declaratory and injunctive relief, class certification, and attorneys' fees and costs.

Related Party Transactions

• The majority of the company's revenue is derived from management services provided to Medical Corporations (MCs) in Japan, where relatives of the CEO hold two-thirds of the voting rights.
• Disposal of SBC Kijimadaira Resort Inc. and Skynet Academy Co., Ltd. in December 2024 to entities owned by CEO Yoshiyuki Aikawa.
• The acquisition of a controlling interest in Waqoo, Inc. in December 2025 included an off-market transaction of shares from CEO Yoshiyuki Aikawa.
• Compensation paid by a subsidiary to Yoshiko Aikawa, the CEO's mother and an officer of that subsidiary, was not timely identified as a related party transaction for Audit Committee review and approval purposes.
• A deemed contribution of approximately $10.35 million was recorded in connection with a price modification on the disposal of an aircraft to General Incorporated Association SBC, an entity controlled by the CEO.
• The company invested in unsecured convertible bonds issued by MEDIROM Healthcare Technologies Inc., where an independent director of the company also serves as a Director and CFO.
• A subsidiary provided a guarantee on the debt of its CEO, amounting to $228,210 as of December 31, 2025.

Stakeholder Impact

• Shareholders face potential dilution from future equity raises, stock price volatility, and limited influence due to the CEO's concentrated voting power (85.2%). They may benefit from the new $20.0 million share repurchase program, but no cash dividends are planned for the foreseeable future.
• Employees are expected to see workforce expansion and benefit from a focus on an inclusive and rewarding environment, but the company faces a competitive hiring landscape and risks related to retaining key personnel.
• Franchisee clinics (MCs) benefit from advanced management services, marketing support, staff recruitment/training, IT solutions, and intellectual property licensing, but are subject to revised fee structures and the company's operational guidelines.
• End-users (patients) gain access to a wider range of cosmetic services through the multi-brand strategy, potentially improved safety and efficiency via technology, and customer loyalty programs.
• Suppliers are part of a diverse network, but face potential impacts from supply chain delays.
• Creditors may be impacted by potential future indebtedness and associated covenants.

Next Steps

• Continue to evaluate other potential investments and acquisitions, such as Risenet Co., Ltd.
• Negotiate a future collaboration agreement with OrangeTwist to explore potential commercial arrangements.
• Make an additional cash contribution of $5.0 million to OT Midco in December 2026.
• Continue to expand the workforce as the company grows.
• Pursue targeted local and global marketing efforts to heighten brand awareness.
• Collect and analyze extensive medical data, develop innovative procedures and products, and obtain intellectual property rights.
• Offer guidance and technical training to franchisee clinics' employees for new products and procedure methodologies.
• Remediate identified material weaknesses in internal control over financial reporting by strengthening control environment, risk assessment processes, and monitoring activities.
• Utilize surplus cash and future free cash flow to fund repurchases under the $20.0 million share repurchase program (effective through December 31, 2026).
• SBC Medical M&A Advisory Co., Ltd. was established on January 7, 2026, to provide healthcare-focused M&A advisory services.

Key Dates

Recommendation

The company presents a mixed financial picture with a notable decline in total revenues but an increase in net income, largely driven by cost reductions and one-time gains rather than core operational growth. Strategic acquisitions and technological investments offer long-term potential, but the persistent material weaknesses in internal controls and the concentrated voting power of the CEO introduce governance risks. While the share repurchase program is a positive signal, the overall uncertainty regarding sustainable revenue growth and the competitive landscape suggests a 'hold' recommendation until there is clearer evidence of sustained operational improvement and full remediation of internal control issues.

Keywords

Cosmetic surgery, Medical aesthetics, Management services, Japan, Singapore, Vietnam, United States, Franchise, SEC filing, 10-K, Financial results, Acquisitions, AI, Regenerative medicine, Corporate governance, Risk management, Share repurchase, Nasdaq, Shonan Beauty Clinic, Internal controls, Related party transactions